See more : Murata Manufacturing Co., Ltd. (6981.T) Income Statement Analysis – Financial Results
Complete financial analysis of IntelGenx Technologies Corp. (IGXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IntelGenx Technologies Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Invesco Mortgage Capital Inc. (IVR-PB) Income Statement Analysis – Financial Results
- Universal Potash Corp. (UPCO) Income Statement Analysis – Financial Results
- Rugby Resources Ltd. (RUG.V) Income Statement Analysis – Financial Results
- Selan Exploration Technology Limited (SELAN.BO) Income Statement Analysis – Financial Results
- Winner Medical Co., Ltd. (300888.SZ) Income Statement Analysis – Financial Results
IntelGenx Technologies Corp. (IGXT)
About IntelGenx Technologies Corp.
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04M | 950.00K | 1.54M | 1.54M | 742.00K | 1.82M | 5.20M | 5.22M | 5.10M | 1.66M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.73M | 1.86M | 2.26M | 1.48M | 0.00 | 0.00 | 373.00K | 319.00K | 433.00K | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -694.00K | -908.00K | -721.00K | 67.00K | 742.00K | 1.82M | 4.82M | 4.90M | 4.66M | 1.60M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -66.79% | -95.58% | -46.97% | 4.34% | 100.00% | 100.00% | 92.82% | 93.89% | 91.50% | 96.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.43M | 3.03M | 2.72M | 2.64M | 3.77M | 5.10M | 2.62M | 1.77M | 1.03M | 1.08M | 561.00K | 1.72M | 1.34M | 1.57M | 1.42M | 2.09M | 603.40K | 510.41K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.76M | 4.70M | 3.75M | 4.44M | 5.80M | 5.00M | 3.97M | 3.61M | 2.07M | 2.29M | 1.95M | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 919.62K | 488.60K | 9.91K | 7.55K | 108.00 |
| Other Expenses | 0.00 | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | -237.90K | -376.84K | -132.37K | 33.91K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.18M | 8.51M | 7.26M | 7.81M | 10.29M | 10.82M | 7.32M | 5.88M | 3.28M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Cost & Expenses | 10.68M | 10.36M | 9.52M | 7.81M | 10.29M | 10.82M | 7.69M | 6.20M | 3.71M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Interest Income | 41.00K | 4.00K | 152.00K | 422.00K | 97.00K | 11.00K | 11.00K | 4.00K | 28.00K | 34.00K | 0.00 | 10.00K | 0.00 | 0.00 | 0.00 | 30.86K | 27.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.28M | 1.49M | 1.20M | 1.21M | 1.12M | 569.00K | 203.00K | 123.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | 784.40K | 766.14K | 349.11K | 54.72K | 1.22K | 297.00 | 0.00 |
| Depreciation & Amortization | 766.00K | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | 44.60K | 51.77K | 42.01K | 33.91K | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.69M | -8.64M | -7.04M | -5.11M | -8.74M | -8.28M | -1.76M | -470.00K | 1.59M | -1.71M | -1.57M | -2.22M | -2.60M | -3.14M | -1.24M | -2.45M | -948.17K | -731.53K | -146.53K | -7.55K | -108.00 |
| EBITDA Ratio | -739.65% | -908.63% | -458.57% | -330.83% | -1,177.22% | -453.29% | -33.63% | -8.93% | 31.11% | -102.83% | -165.30% | -178.81% | -547.50% | -221.24% | -97.11% | -219.13% | -68.71% | -290.98% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.49M | -9.41M | -7.98M | -6.26M | -9.55M | -9.00M | -2.49M | -981.00K | 1.39M | -1.78M | -1.64M | -2.21M | -2.45M | -3.00M | -1.29M | -2.19M | -729.62K | -767.02K | -9.91K | -7.55K | -108.00 |
| Operating Income Ratio | -913.47% | -990.84% | -520.00% | -405.70% | -1,287.06% | -493.31% | -47.99% | -18.79% | 27.20% | -107.29% | -172.89% | -182.62% | -555.91% | -224.53% | -100.60% | -224.43% | -87.34% | -288.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -436.00K | -1.28M | -1.34M | -780.00K | -1.11M | -1.11M | -558.00K | -199.00K | -95.00K | 34.00K | 0.00 | 10.00K | 172.00K | -558.00K | -686.70K | -306.67K | -196.81K | -14.12K | 35.29K | 0.00 | 0.00 |
| Income Before Tax | -9.93M | -10.69M | -9.32M | -7.04M | -10.66M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -2.07M | -2.96M | -1.16M | -781.14K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -955.44% | -1,125.26% | -607.04% | -456.22% | -1,436.66% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -161.94% | -302.88% | -139.44% | -293.77% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.28M | -6.00K | 1.20M | 1.21M | 11.00K | 11.00K | 4.00K | 28.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | -130.30K | -151.58K | -64.08K | 14.12K | 11.12K | 7.84K | 108.00 |
| Net Income | -9.93M | -11.97M | -9.31M | -8.25M | -11.87M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -1.94M | -2.81M | -1.10M | -781.14K | -11.12K | -7.84K | -108.00 |
| Net Income Ratio | -955.44% | -1,259.68% | -606.64% | -534.07% | -1,599.33% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -151.75% | -287.36% | -131.77% | -293.77% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 63.52M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 70.86M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting
SAINT LAURENT, Quebec, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) wishes to remind its shareholders of record as of October 2, 2023 (the “Shareholders”) of the importance of a vote FOR the various...
IntelGenx Technologies Corp. (IGXT) Q3 2023 Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Dwight Gorham – Chief Executive Officer Andre Godin – President and Chief Financial Officer Tommy Kenny – Senior...
IntelGenx Reports Third Quarter 2023 Financial Results
SAINT LAURENT, Quebec, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...
IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray
IntelGenx to Manufacture and Supply Three New Filmstrip Products: CBD20, THC10, and THC10:CBD10 IntelGenx to Manufacture and Supply Three New Filmstrip Products: CBD20, THC10, and THC10:CBD10
IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow
SAINT LAURENT, Quebec, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2023 financial results after market close on Thursday, November 9, 2023.
IntelGenx Provides RIZAFILM® U.S. Commercialization Update
SAINT LAURENT, Quebec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has received the first purchase order (“PO”) for RIZAFILM®1 from its commercial partner in the United States, Gensco Pharma (“Gensco®”).
IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtained)
SAINT LAURENT, Quebec, Aug. 31, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the first tranche of a non-brokered private placement (the “Offering”) of units (“Units”) from atai Life Sciences AG (“atai”)...
IntelGenx Technologies Corp. (IGXT) Q2 2023 Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Dwight Gorham - Chief Executive Officer Andre Godin - President and CFO Dr. David Kideckel - Senior Vice...
IntelGenx Reports Second Quarter 2023 Financial Results
SAINT LAURENT, Quebec, Aug. 14, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter ended June 30, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...
IntelGenx Announces First Agreement for CDMO Packaging Services
Expected to generate approximately $9 million in revenue for IntelGenx over three years Expected to generate approximately $9 million in revenue for IntelGenx over three years
Source: https://incomestatements.info
Category: Stock Reports